84-4445-69　［取扱停止］Zika Virus NS1 (Zika Virus Nonstructural Protein 1) 1mg　367973

特徴

• In 1947, the mosquito-borne Zika virus (ZIKV) was first isolated from a rhesus monkey in the Zika forest of Uganda. In 1968, isolation from human hosts occurred in residents of Nigeria. Multiple studies have confirmed ZIKV antibody in humans from a multitude of countries in Africa and parts of Asia. In 2015, ZIKV first appeared outside of Africa and Asia when it was isolated in Brazil.
• ZIKV is closely related to other mosquito-borne flaviviruses such as the dengue, Japanese encephalitis, yellow fever, West Nile viruses. ZIKV causes a disease known as Zika fever, which is characterized by a macropapular rash covering the body, fever, joint pain, and malaise. ZIKV is an important emerging pathogen due to its appearance across the globe, mosquito-driven transmission cycle, and possible spread via sexual contact. Studies have shown that ZIKV can reside in blood transfusions and they can be a possible vector for human-to-human transmission.
• Diagnosis for ZIKV infection include PCR tests to detect viral DNA as well as additional tests to detect ZIKV antibody (IgM) in serum.
• IgM for ZIKV is typically detectable around 3-5 days after infection, but cross-reactivity with closely related dengue, yellow fever, Japanese encephalitis, and West Nile viruses are possible.
• There is no vaccine for ZIKV or treatment for Zika fever. Symptoms are relatively mild and only supportive therapy is employed.
• Applications:Suitable for use in ELISA.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.